Vergote, I B <br/><br/>
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.  [electronic resource] 

 -  Gynecologic oncology  02 2020 
 - 308-314 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2019.11.012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Cohort Studies<br/>Female<br/>Genital Neoplasms, Female--drug therapy<br/>Humans<br/>Hydrazines--administration & dosage<br/>Karyopherins--antagonists & inhibitors<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Recurrence, Local--drug therapy<br/>Progression-Free Survival<br/>Receptors, Cytoplasmic and Nuclear--antagonists & inhibitors<br/>Triazoles--administration & dosage<br/>Exportin 1 Protein